A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases
Cardiovascular diseases (CVDs) are a major threat to public health globally. A large proportion of people with dyslipidaemia have poorly controlled lipid levels, emphasizing the need for alternative lipid-lowering treatments that are both effective and safe. Xuezhikang, a red yeast rice (RYR) extrac...
Saved in:
| Main Authors: | Cheng Yang, Yongjian Wu, Jie Qian, Jian-Jun Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-10-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383524001886 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)
by: M. V. Ezhov, et al.
Published: (2020-03-01) -
Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial
by: Nafrialdi Nafrialdi, et al.
Published: (2019-05-01) -
Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial
by: Nafrialdi Nafrialdi, et al.
Published: (2019-05-01) -
Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience
by: Alessia Izzo, et al.
Published: (2024-11-01) -
Beneficial Effects of a Nutraceutical Combination on Lipid Profiles in Children with Moderate and Severe Hypercholesterolemia
by: Anastasia Garoufi, et al.
Published: (2024-12-01)